Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
4.130
-1.340 (-24.50%)
At close: May 2, 2025, 4:00 PM
4.180
+0.050 (1.21%)
After-hours: May 2, 2025, 5:13 PM EDT
Ardelyx Employees
Ardelyx had 395 employees as of December 31, 2024. The number of employees increased by 128 or 47.94% compared to the previous year.
Employees
395
Change (1Y)
128
Growth (1Y)
47.94%
Revenue / Employee
$915,711
Profits / Employee
-$136,106
Market Cap
988.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ARDX News
- 16 hours ago - Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty - Seeking Alpha
- 1 day ago - Ardelyx, Inc. (ARDX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 days ago - Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
- 8 days ago - Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference - GlobeNewsWire
- 15 days ago - Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 22 days ago - Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings - GlobeNewsWire
- 4 weeks ago - Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - GlobeNewsWire